These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28955143)

  • 1. New Drug Research and Development for Alzheimer's Pathology: Present and Prospect.
    Wang T
    Shanghai Arch Psychiatry; 2017 Aug; 29(4):237-239. PubMed ID: 28955143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
    Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
    Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
    Shi M; Chu F; Zhu F; Zhu J
    Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
    Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
    Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying treatments for Alzheimer's disease.
    Galimberti D; Scarpini E
    Ther Adv Neurol Disord; 2011 Jul; 4(4):203-16. PubMed ID: 21765871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives.
    Pardo-Moreno T; González-Acedo A; Rivas-Domínguez A; García-Morales V; García-Cozar FJ; Ramos-Rodríguez JJ; Melguizo-Rodríguez L
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.
    Yan R
    Transl Neurodegener; 2016; 5():13. PubMed ID: 27418961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development for Alzheimer's disease: recent progress.
    Ji W; Ha I
    Exp Neurobiol; 2010 Dec; 19(3):120-31. PubMed ID: 22110351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
    Siemers E; DeMattos RB; May PC; Dean RA
    Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
    Melchiorri D; Merlo S; Micallef B; Borg JJ; Dráfi F
    Front Pharmacol; 2023; 14():1196413. PubMed ID: 37332353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.